WAY127093B racemate

CAS No. 145743-63-1

WAY127093B racemate( —— )

Catalog No. M33170 CAS No. 145743-63-1

WAY127093B racemate is the racemic mixture of WAY127093B, a phosphodiesterase IV inhibitor with demonstrated oral activity in rats and guinea pigs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 119 In Stock
5MG 107 In Stock
10MG 158 In Stock
25MG 236 In Stock
50MG 326 In Stock
100MG 437 In Stock
200MG 579 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WAY127093B racemate
  • Note
    Research use only, not for human use.
  • Brief Description
    WAY127093B racemate is the racemic mixture of WAY127093B, a phosphodiesterase IV inhibitor with demonstrated oral activity in rats and guinea pigs.
  • Description
    WAY127093B racemate is the racemate of WAY127093B. WAY127093B is an orally active phosphodiesterase IV inhibitor in guinea pigs and rats.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    145743-63-1
  • Formula Weight
    424.49
  • Molecular Formula
    C23H28N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1C(CC(=O)N1C(NCC=2C=CC=NC2)=O)C3=CC(OC4CCCC4)=C(OC)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Howell RE, et al. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Inflamm Res. 1995 Aug;44 Suppl 2:S172-3.?
molnova catalog
related products
  • Avanafil

    A potent and highly selective PDE5 inhibitor (IC50=5.2 nM) for erectile dysfunction.

  • Ensifentrine

    Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

  • BRL 50481

    BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15 12.1 62 and 490 μM for PDE7A PDE7B PDE4 and PDE3 respectively.